Cargando…

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baty, Florent, Rothschild, Sacha, Früh, Martin, Betticher, Daniel, Dröge, Cornelia, Cathomas, Richard, Rauch, Daniel, Gautschi, Oliver, Bubendorf, Lukas, Crowe, Susanne, Zappa, Francesco, Pless, Miklos, Brutsche, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769372/ https://www.ncbi.nlm.nih.gov/pubmed/24039832 http://dx.doi.org/10.1371/journal.pone.0072966

Ejemplares similares

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
por: Baty, Florent, et al.
Publicado: (2017)

Tumour neoantigen mimicry by microbial species in cancer immunotherapy
por: Boesch, Maximilian, et al.
Publicado: (2021)

Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
por: Boesch, Maximilian, et al.
Publicado: (2021)

Acute Fatal Liver Toxicity under Erlotinib
por: Schacher-Kaufmann, Sabina, et al.
Publicado: (2010)

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019)

Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study
por: Fuchs, Julia, et al.
Publicado: (2021)

Non-pharmaceutical interventions to optimize cancer immunotherapy
por: Boesch, Maximilian, et al.
Publicado: (2023)

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
por: Rothschild, Sacha I., et al.
Publicado: (2019)

In-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012
por: Pohle, Susanne, et al.
Publicado: (2016)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Stability of gene contributions and identification of outliers in multivariate analysis of microarray data
por: Baty, Florent, et al.
Publicado: (2008)

Modeling the oxygen uptake kinetics during exercise testing of patients with chronic obstructive pulmonary diseases using nonlinear mixed models
por: Baty, Florent, et al.
Publicado: (2016)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Comorbidities and Burden of COPD: A Population Based Case-Control Study
por: Baty, Florent, et al.
Publicado: (2013)

Identification of smoking cessation phenotypes as a basis for individualized counseling: An explorative real-world cohort study
por: Paciorkowski, Maciej, et al.
Publicado: (2022)

In-hospital survival paradox in patients with sleep apnea—A nation-wide nested case-control study
por: Moser, Maurice, et al.
Publicado: (2022)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
por: König, D., et al.
Publicado: (2023)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
por: Helfenstein, Seth, et al.
Publicado: (2019)

Analysis with respect to instrumental variables for the exploration of microarray data structures
por: Baty, Florent, et al.
Publicado: (2006)

Gender-specific disease trajectories prior to the onset of COPD allow individualized screening and early intervention
por: Hagmann, Michelle, et al.
Publicado: (2023)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Exploring the transcription factor activity in high-throughput gene expression data using RLQ analysis
por: Baty, Florent, et al.
Publicado: (2013)

Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities
por: Walter, Anna-Lena, et al.
Publicado: (2021)

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
por: Agbarya, Abed, et al.
Publicado: (2014)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Optimized between-group classification: a new jackknife-based gene selection procedure for genome-wide expression data
por: Baty, Florent, et al.
Publicado: (2005)

OMIP 077: Definition of all principal human leukocyte populations using a broadly applicable 14‐color panel
por: Boesch, Maximilian, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
por: Schwitter, Michael, et al.
Publicado: (2013)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
por: Petrausch, Ulf, et al.
Publicado: (2023)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gg94uo4nmunrb381d00fq5b1rk